Improving Management of Patients at High Risk for Osteoporotic Fractures

This study has been completed.
Sponsor:
Information provided by:
Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier:
NCT00139438
First received: August 29, 2005
Last updated: October 25, 2009
Last verified: October 2009

August 29, 2005
October 25, 2009
September 2004
June 2005   (final data collection date for primary outcome measure)
A composite measure of bone mineral density (BMD) testing and/or osteoporosis medications prescriptions.
Bone mineral density (BMD) testing rates
Complete list of historical versions of study NCT00139438 on ClinicalTrials.gov Archive Site
BMD testing, osteoporosis medication prescriptions, fracture
Osteoporosis medication treatment rates and medication
Not Provided
Not Provided
 
Improving Management of Patients at High Risk for Osteoporotic Fractures
Improving Management of Patients at High Risk for Osteoporotic Fractures

The purpose of this study is to assess the impact of disease management interventions on percent receiving a bone densitometry test and percent appropriately prescribed a medication for osteoporosis.

Not Provided
Interventional
Not Provided
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Open Label
Osteoporosis
Behavioral: Disease Management Assessment
Not Provided
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
4266
Not Provided
June 2005   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Members of the Horizon Blue Cross Blue Shield of New Jersey who are at risk for osteoporosis based on age (women age 65 or older, men and women age 45 or older who have a history of fragility fracture or have a history of taking oral glucocorticoids over 3 months).

Exclusion Criteria:

  • Individuals who are not members of Horizon Blue Cross Blue Shield of New Jersey and who otherwise do not meet the inclusion criteria.
Both
45 Years and older
No
Contact information is only displayed when the study is recruiting subjects
Not Provided
 
NCT00139438
2005_049, 038
Not Provided
Executive Vice President, Clinical and Quantitative Sciences, Merck & Co., Inc.
Merck Sharp & Dohme Corp.
Not Provided
Principal Investigator: Daniel H. Solomon, M.D., M.P.H. Brigham and Woman's Hospital
Merck Sharp & Dohme Corp.
October 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP